We're announcing an agreement with the @EU_Commission to amend their originally agreed contractual delivery schedules for our #COVID19 vaccine (mRNA-1273) booster product or updated booster vaccine candidate.
investors.modernatx.com/news/news-deta…
investors.modernatx.com/news/news-deta…
This amendment allows participating Member States to have our COVID-19 #vaccine booster doses scheduled for delivery in the second quarter of 2022 to be delivered later in calendar year 2022 or early calendar year 2023.
Participating Member States will have the possibility to receive the expected updated bivalent #booster candidate following approval by the @EMA_News.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
